Investors & Media Press Releases

Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference


NEW YORK and BASEL, Switzerland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference on March 1, 2019 at 11:00 a.m. (Eastern Time).

A live webcast will be available in the Events section of Axovant's website at A replay will be available for approximately 30 days following the conference.

About Axovant

Axovant Sciences is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit


Mike Beyer
Sam Brown Inc.
(312) 961-2502

Tricia Truehart
(631) 892-7014


AXOVANT Full Color Logo 2018OCT31 XSMALL F-01.jpg

Source: Axovant Sciences Ltd.